Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)

Craig A. Portell, Opeyemi Jegede, N. Nora Bennani, Seema Naik, Christopher M. Reynolds, Priyank P. Patel, Michael J. Robertson, Brad S. Kahl

Blood (2023) 142 (Supplement 1): 733.

https://doi.org/10.1182/blood-2023-182374

Published: 2023

Journal Articles

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2 ) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason Melear, Suzanne Fanning, Kathryn S. Kolibaba, Christopher M. Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman

Blood (2021) 138 (Supplement 1): 812.

https://doi.org/10.1182/blood-2021-145640

Published: 2021

Journal Articles

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Morton Coleman, MD FACP, David Jacob Andorsky, MD, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Frederick Lansigan, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-134363

Published: 2020

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, MD, David Jacob Andorsky, MD, Morton Coleman, MD FACP, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134193

Published: 2020

Journal Articles

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Craig A. Portell, MD, N. Nora Bennani, MD, Opeyemi Jegede, PhD, Seema Naik, MD, Benjamin M Parsons, DO, Priyank P Patel, MD, Christopher M. Reynolds, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 5243.

https://doi.org/10.1182/blood-2019-122759

Published: 2019

Journal Articles

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Brian GM Durie, MD, Antje Hoering, PhD, Rachael Sexton, PhD, Muneer H. Abidi, MD, Joshua Epstein, DSc, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J. Reu, MD, Christopher M. Reynolds, MD, Robert Z. Orlowski, MD PhD, Bart Barlogie, MD PhD

Blood (2018) 132 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2018-99-117003

Published: 2018

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Brian Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Muneer H. Abidi, MD, Joshua Epstein, DSc, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J Reu, Christopher M. Reynolds, MD, Rachael Sexton, MS, Robert Z. Orlowski, PhD, MD, Bart Barlogie, MD PhD, Angela Dispenzieri, MD

Blood (2015) 126 (23): 25.

https://doi.org/10.1182/blood.V126.23.25.25

Published: 2015

Journal Articles

Keratinocyte Growth Factor Factor (Palifermin) in Combination with Tacrolimus and Methotrexate for the Prevention of Acute Graft-Vs-Host Disease (aGVHD) in Patients at High Risk of Agvhd.

Christopher M. Reynolds, MD, John E. Levine, MD, Joseph P. Uberti, MD, Voravit Ratanatharathorn, MD, Lois J. Ayash, MD, Samuel M. Silver, MD, Gregory A. Yanik, MD, Pavan R. Reddy, MD, Cooke R. Kenneth, MD, Becker W. Michael, MD, Hutchinson J. Raymond, MD, L. J Ferrara, MD

Blood (2004) 104 (11): 1228.

https://doi.org/10.1182/blood.V104.11.1228.1228

Published: 2004

NARROW

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2 ) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Keratinocyte Growth Factor Factor (Palifermin) in Combination with Tacrolimus and Methotrexate for the Prevention of Acute Graft-Vs-Host Disease (aGVHD) in Patients at High Risk of Agvhd.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only